2022 World Conference on Lung Cancer (ePosters)-EP14.01-010. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer

EP14.01-010. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer

Back to course

Pdf Summary

The objective of the CAN study is to investigate the efficacy and safety of combination therapy with niraparib and anlotinib in patients with recurrent small cell lung cancer (SCLC). SCLC is a type of lung cancer associated with a poor prognosis and limited treatment options after relapse.<br /><br />Previous studies have shown that anlotinib, a multi-target receptor tyrosine kinase inhibitor, can inhibit angiogenesis and has been approved for the third or further-line treatment of SCLC. Niraparib, a PARP1 and PARP2 inhibitor, has also shown promise in extending progression-free survival (PFS) in platinum-responsive SCLC.<br /><br />The CAN study aims to assess the objective response rate (ORR) as the primary outcome, along with secondary outcomes such as safety data, duration of response (DOR), disease control rate (DCR), PFS, and overall survival (OS). The study will also explore biomarkers associated with the efficacy of the combination therapy.<br /><br />The study is funded by Zailab company and is currently ongoing. It follows an open-label, single-center, prospective, and single-arm phase II study design. Patients included in the study must have histologically diagnosed SCLC and have failed at least one previous systemic platinum-based chemotherapy. They should also have measurable target lesions according to RECIST 1.1 criteria.<br /><br />The treatment regimen involves daily administration of niraparib, either at a dose of 300mg or 200mg, along with anlotinib at a dose of 12mg. The treatment is continued in 21-day cycles until disease progression, intolerable toxicity, death, or patient withdrawal of consent.<br /><br />Overall, the CAN study aims to assess the effectiveness and safety of combining niraparib and anlotinib in recurrent SCLC patients, potentially providing a new treatment option for this challenging disease.

Asset Subtitle

Ying Cheng

Meta Tag

Speaker Ying Cheng

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

CAN study

combination therapy

niraparib

anlotinib

recurrent small cell lung cancer

SCLC

efficacy

safety

angiogenesis inhibition

PARP inhibitors